Search
Clorobiocin
go.drugbank.com/drugs/DB03966ExperimentalClorobiocin is an aminocoumarin antibiotic, similar to [novobiocin] and coumermycin A1.
Hydroxydione
go.drugbank.com/drugs/DB08956ApprovedWithdrawnHydroxydione (Viadril) is a neuroactive steroid used as a general anesthetic.
Iopanoic acid
go.drugbank.com/drugs/DB08946ApprovedWithdrawnIopanoic acid contains iodine and is useful as a contrast medium in cholecystography.
Categories: Compounds used in a research, industrial, or household settingPhenylmercuric acetate
go.drugbank.com/drugs/DB17044ExperimentalPhenylmercuric acetate is an organomercurial compound used as a fungicide and slimicide.[A253082]
Categories: Compounds used in a research, industrial, or household settingNeltenexine
go.drugbank.com/drugs/DB13239InvestigationalNeltenexine is an elastase inhibitor. It may be useful for preventing pulmonary emphysema.
Benziodarone
go.drugbank.com/drugs/DB13277ApprovedWithdrawnBenziodarone is a uricostatic and a uricosuric agent which is sold also under the name Amplivex-Labaz. It is used in the treatment of gout [A175630]. … It was withdrawn from France markets and British markets due to its effects causing Jaundice in patients [T487, A175636].
Defactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigational[L53198,L53208] FAK is important for the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key … Defactinib is a small molecule kinase inhibitor targeted against focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2), the two members of the FAK family of nonreceptor tyrosine kinases
Arbaclofen Placarbil
go.drugbank.com/drugs/DB08892InvestigationalIt was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties. … Arbaclofen Placerbil is a prodrug of Arbaclofen, which is a selective gamma-amino-butyric acid type B receptor agonist and the R-enantiomer of baclofen.
Osanetant
go.drugbank.com/drugs/DB04872InvestigationalIn a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. … This follows an earlier decision to discontinue development of eplivanserin for schizophrenia.
TC-2216
go.drugbank.com/drugs/DB06044InvestigationalTC-2216 is an investigational novel small molecule that is being developed as an oral treatment for depression and anxiety disorders. … TC-2216 showed greater potency than and anti-depressant effects comparable to selective serotonin reuptake inhibitors and tricyclics, which are commonly used treatments for depression, as well as anxiety-relieving